Prospective studies : Why such a limited benefit
Modest short-term virological benefit seen in arms either genotype or phenotype
Differences between resistance arms and SOC
- patients with VL-500 copies/ml = 15%-20%
- modest benefit in part due to improper interpretation of genotypic results (algorithms) and unknown clinical cut-off for phenotypes
- cross-resistance with present drugs: lack of new active drugs
- possible role of undetected resistant minority species